Values First Advisors Inc. Invests $684,000 in TransMedics Group, Inc. (NASDAQ:TMDX)

Values First Advisors Inc. bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 8,665 shares of the company’s stock, valued at approximately $684,000.

Several other large investors have also recently made changes to their positions in the company. Huntington National Bank bought a new stake in TransMedics Group during the second quarter worth approximately $30,000. Comerica Bank bought a new stake in TransMedics Group during the third quarter worth approximately $34,000. Global Retirement Partners LLC bought a new stake in TransMedics Group during the third quarter worth approximately $38,000. Cutler Group LLC CA increased its stake in TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after acquiring an additional 600 shares during the last quarter. Finally, Ancora Advisors LLC bought a new stake in TransMedics Group during the first quarter worth approximately $38,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Down 0.2 %

Shares of NASDAQ TMDX traded down $0.18 during mid-day trading on Friday, hitting $73.94. The stock had a trading volume of 876,931 shares, compared to its average volume of 700,890. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The company has a 50 day moving average of $83.45 and a two-hundred day moving average of $70.01. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $99.63.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The firm had revenue of $81.20 million for the quarter, compared to the consensus estimate of $68.49 million. During the same period in the prior year, the firm earned ($0.21) EPS. The firm’s revenue was up 158.6% on a year-over-year basis. As a group, equities research analysts forecast that TransMedics Group, Inc. will post -0.22 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 10,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $80.41, for a total value of $804,100.00. Following the sale, the insider now directly owns 14,375 shares of the company’s stock, valued at $1,155,893.75. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CFO Stephen Gordon sold 15,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $77.07, for a total transaction of $1,156,050.00. Following the sale, the chief financial officer now directly owns 13,075 shares of the company’s stock, valued at approximately $1,007,690.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 10,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.41, for a total transaction of $804,100.00. Following the sale, the insider now directly owns 14,375 shares in the company, valued at $1,155,893.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 92,949 shares of company stock valued at $7,710,719. 6.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TMDX has been the subject of several recent analyst reports. Morgan Stanley boosted their target price on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Piper Sandler began coverage on TransMedics Group in a report on Thursday. They issued an “overweight” rating and a $95.00 price target for the company. JPMorgan Chase & Co. boosted their price target on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Finally, Oppenheimer upped their target price on TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $102.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.